Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIa, double-blind, randomised, placebo-controlled, dose-finding study on the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controlled celiac disease undergoing gluten challenge

Next Previous
X
Search
Trial Profile

A phase IIa, double-blind, randomised, placebo-controlled, dose-finding study on the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controlled celiac disease undergoing gluten challenge

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZED 1227 (Primary)
  • Indications Coeliac disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Dr Falk Pharma

    • Most Recent Events

    • 01 Jul 2021 Primary endpoint has been met (Attenuation of gluten-induced change in intestinal mucosal morphology upon biopsy morphometrically measured) , according to Results published in the New England Journal of Medicine
    • 01 Jul 2021 Status changed to completed , according to Results published in the New England Journal of Medicine
    • 01 Jul 2021 Results published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top